```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, functions as a valuable research reagent extensively used in cardiovascular studies . This antibody fragment specifically targets the glycoprotein IIb/IIIa binding site on platelets , inhibiting clot formation . Therefore , it's commonly applied as a method to analyze the processes underlying thrombosis and to evaluate the effectiveness of anticoagulant medications . Availability is typically controlled to institutional settings.
```
Abciximab Research: Utilizing C7E3 Antibody and The 143653-53-6 Substance in Studies
Ongoing research into abciximab, a antiplatelet agent, frequently employs the monoclonal antigen C7E3 and the chemical compound identified as 143653-53-6. These materials are essential for examining abciximab's biological activity, evaluating its efficacy in different patient populations, and understanding potential predictors of patient outcome. Additional exploration leveraging these specific reagents is predicted to yield valuable data for enhancing clinical applications concerning cardiovascular conditions.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Investigating Research Possibilities with this Glycoprotein IIb/IIIa Inhibitor 143653-53-6 using C7E3
Recent research suggest that check here this antiplatelet agent (identified as 143653-53-6) holds significant investigative potential, particularly when combined with a C7E3 construct. Preliminary findings suggested that this combination might improve patient results in various arterial settings. Further investigation is centered on defining the precise mechanism of action between Abciximab and C7E3, including study of blood clot cohesion and arterial preservation.
- Ongoing study work seek to optimize dosing approaches.
- Preclinical models are are being employed to additional confirm such hypotheses.
- Clinical assessments will be necessary to thoroughly assess patient effectiveness.
```
Abciximab (C7E3) for Research: Quality and Details (143653-53-6)
Researchers needing abciximab for laboratory investigations should rigorously evaluate purity and documented characteristics. Material 143653-53-6 is typically supplied as a freeze-dried powder and detailed analytical data including identity by LC-MS, binding affinity assays, and endotoxin level testing are available. Ensure the supplier's CoA clearly states defined values for contaminants and conforms to all quality control guidelines.
High-Purity C7E3 Details & Availability
Acquiring analytical-grade Abciximab, specifically referencing the antibody C7E3 and identified by the product number 143653-53-6, requires detailed consideration of its origin . This agent is frequently utilized in cell-based experiments, particularly those involving platelet adhesion and clotting . Current sources offer this substance in varying amounts , typically ranging from milligram to larger commercial quantities . Kindly advise reviewing the documentation of testing to verify purity and suitability for your specific application . Moreover, check the shelf life date before procuring to maintain optimal performance .
- Typical Purity: >95%
- Storage Conditions: -20°C in controlled conditions
- Intended Purpose: Platelet Clumping Blocking Studies